Although the treatment improved the hypertrophic cardiomyopathy, the infant unfortunately died of pulmonary hypertension suggesting that MEK inhibitors are not sufficient to reverse pulmonary vascular disease. Here, MAP2K7 is linked to hypertrophic cardiomyopathy.